Corbus Pharmaceuticals Holdings received a patent confirmation for their claim of using pharmaceutical compositions comprising anabasum.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) received a patent confirmation for their claim of using pharmaceutical compositions comprising anabasum.
As quoted in the press release:
The patent provides intellectual property protection for Corbus’ use of anabasum to treat inflammatory diseases in the United States through 2034.
The patent is part of an expanding and comprehensive portfolio of patent applications and other intellectual property addressing the synthesis, manufacturing, formulation and uses of anabasum for a variety of indications including the Company’s lead indications: systemic sclerosis, dermatomyositis, cystic fibrosis and systemic lupus erythematosus. Anabasum is a synthetic oral endocannabinoid-mimetic drug candidate designed to resolve chronic inflammation and fibrotic processes through the activation of the cannabinoid receptor Type 2 (“CB2”).